NeuroPace Inc NPCE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
-
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
-
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
-
NeuroPace's Panel Track Supplement Not Approvable in Current Form, FDA Says
-
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
Trading Information
- Previous Close Price
- $13.87
- Day Range
- $13.82–14.13
- 52-Week Range
- $9.22–19.60
- Bid/Ask
- $13.75 / $14.07
- Shares Outstanding
- 34.32M
- Market Cap
- $481.91M
- Volume/Avg
- 107,481 / 184,783
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.01%
Company Profile
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 220
- Website
- https://www.neuropace.com
Valuation
|
Metric
|
NPCE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 40.02 |
Price/Sales | 4.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NPCE
|
|---|---|
Quick Ratio | 3.82 |
Current Ratio | 4.94 |
Interest Coverage | −2.42 |
Quick Ratio
NPCE
Profitability
|
Metric
|
NPCE
|
|---|---|
Return on Assets (Normalized) | −8.73% |
Return on Equity (Normalized) | −53.94% |
Return on Invested Capital (Normalized) | −5.81% |
Return on Assets
NPCE
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|?@>s>n | LOCK|GYb@B | $179B | |||
| Medtronic PLC
MDT
| LOCK|XbRZ<% | LOCK|&DwL | $117B | |||
| Stryker Corp
SYK
| LOCK|BySWJW@f | LOCK|vgs | $104B | |||
| Boston Scientific Corp
BSX
| LOCK|L?>h>z% | LOCK|dtQn | $62B | |||
| Edwards Lifesciences Corp
EW
| LOCK|pJhsTqb | LOCK|!X^Zz | $50B | |||
| DexCom Inc
DXCM
| LOCK|@&?rhKf? | LOCK|WBbwB | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|%%q?<x | LOCK|#X | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|<W& | LOCK|^^ | $24B | |||
| Steris PLC
STE
| LOCK|rwg!N> | LOCK|QV@q | $21B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|@m>S$&@ | LOCK|mH | $18B |
United States